Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. on October 3, 2014, covering events occurring between October 3 and October 9, 2014. The filing addresses significant changes in the Company's executive leadership structure.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.

Material Changes

  • Appointment: Thomas Looby was appointed President and Chief Commercial Officer, effective October 8, 2014. He will oversee Sales, Marketing, Clinical, Customer Service, and Quality departments, reporting to CEO Nathan Harding.
  • Departure: Frank Moreman's employment as Chief Operating Officer terminated effective October 3, 2014.
  • Background: Mr. Looby joined the Company in April 2014 as Chief Marketing Officer. Prior experience includes roles at Given Imaging and Eastman Kodak.

Guidance, Outlook, and Risks

The filing does not contain financial guidance, forward-looking outlook statements, or specific risk factors. It notes that the press release regarding Mr. Looby's appointment is furnished as an exhibit and is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Investor Verification Checklist

  • Verify the effective dates of the leadership transition (October 3 for departure, October 8 for appointment).
  • Confirm the specific scope of Thomas Looby's new responsibilities across five key departments.
  • Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for these changes.
  • Check subsequent filings for any impact on the Company's operational strategy following the departure of the Chief Operating Officer.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.